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Fioole et al report 51 patients treated with percutaneous
angioplasty and stenting (PTAS) for chronic mesenteric ischemia
(CMI), reflecting the authors’ transition towards a PTAS-first
approach to CMI. They report very acceptable primary patency,
secondary patency, and clinical success at 2 years of 60%, 79%, and
56%, respectively. This article is important, because the transition
to endovascular-first treatment for CMI is not limited to this group
but has been observed in many vascular practices. This report
highlights the continued tradeoff of newer, less invasive treat-
ments, and lower morbidity at the expense of durability and higher
reintervention rates compared with open surgery.
A less invasive procedure may tend to overtreat patients with
unclear or minimal symptoms. The current report includes pre-
dominately multivessel disease, but seven patients with single-
vessel disease and “insufficient collaterals” were included. Impor-
tantly, the authors used a multidisciplinary approach to diagnosis,
with the involvement of vascular surgeons, interventional radiolo-
gists, and gastroenterologists. Also, the authors recognize the
emerging role of exercise tonometry. Despite careful consider-
ation, there were two treatment failures due to underlying infec-
tious causes.
In the era of open surgical revascularization, the technical
discussion focused on single vs multiple revascularization and
antegrade vs retrograde bypass. With PTAS, the real discussion
appears to be single-vessel vs multivessel revascularization. Most of
the patients with multivessel disease had single-vessel revascular-
ization, with reliance on visualized collaterals, whereas in only sixrevascularization only. This logic flaw is demonstrated by the open
revascularization procedures necessary in 14% of the patients,
which all involved direct SMA revascularization. The limitation in
crossing chronic occlusions in the visceral vessels needs to be
addressed. This report includes only a single revascularization of a
chronically occluded SMA. Until complete SMA revascularization
is possible, PTAS is not anatomically equivalent to surgical revas-
cularization for CMI.
Surgeons need to carefully view the emerging data on PTAS
for CMI.1-3 The question is whether PTAS is a reasonable first-line
therapy based on the data, or because surgeons now perform
PTAS. From a patient perspective, however, less may be better.
Major morbidity was only 4%. But what is the cost? The authors,
unfortunately, do not provide this information. With a 2-year
primary patency of only 60%, repeat interventions may be the
norm. Within the current health care environment, this is an
excellent opportunity for comparative-effectiveness research.
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